Departments of Gynecology, Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
Int J Gynecol Cancer. 2010 Jul;20(5):745-50. doi: 10.1111/IGC.0b013e3181e02f90.
Lysosomal protein transmembrane 4 β-35 (LAPTM4B-35), a novel oncoprotein that belongs to the mammalian 4-tetratransmembrane spanning protein superfamily, has been implicated in oncogenesis and cancer progression in several solid malignances. However, the expression of LAPTM4B-35 and its role in endometrial cancer progression remain unknown.
We investigated the expression of the LAPTM4B-35 protein by immunohistochemistry in 30 normal endometrium specimens and 165 endometrial carcinomas and analyzed its correlation with various clinicopathologic features, including patient outcome.
LAPTM4B-35 immunoreactivity was overexpressed in endometrial carcinoma cases compared with normal endometrium (P < 0.001). High LAPTM4B-35 expression was found in 117 (70.91%) of these 165 carcinomas and was positively correlated with the International Federation of Gynecology and Obstetrics stage, histological grade, depth of myometrial invasion, lymph node metastasis, lymph vascular space involvement, and recurrence, but not with age and histological type. Patients with high LAPTM4B-35 expression had significantly poorer overall survival and disease-free survival compared with patients with low expression of LAPTM4B-35 (P = 0.001 and P = 0.002, respectively). Multivariate analysis showed that high LAPTM4B-35 expression was an independent prognostic factor for both overall survival and disease-free survival of patients with endometrial carcinoma (both P = 0.005).
These results showed that high LAPTM4B-35 expression was associated with progression and prognosis of endometrial carcinoma.
溶酶体蛋白跨膜 4β-35（LAPTM4B-35）是一种新型的癌蛋白，属于哺乳动物四跨膜蛋白超家族，与多种实体恶性肿瘤的发生和癌症进展有关。然而，LAPTM4B-35 的表达及其在子宫内膜癌进展中的作用尚不清楚。
我们通过免疫组织化学法检测了 30 例正常子宫内膜标本和 165 例子宫内膜癌中 LAPTM4B-35 蛋白的表达，并分析了其与各种临床病理特征的相关性，包括患者的预后。
与正常子宫内膜相比，子宫内膜癌病例中 LAPTM4B-35 免疫反应性过表达（P<0.001）。在这 165 例癌中，有 117 例（70.91%）表达高 LAPTM4B-35，且与国际妇产科联合会分期、组织学分级、肌层浸润深度、淋巴结转移、淋巴管血管间隙浸润和复发呈正相关，与年龄和组织学类型无关。与 LAPTM4B-35 低表达的患者相比，LAPTM4B-35 高表达的患者总生存率和无病生存率明显更差（P=0.001 和 P=0.002）。多因素分析显示，LAPTM4B-35 高表达是子宫内膜癌患者总生存率和无病生存率的独立预后因素（均 P=0.005）。
这些结果表明，LAPTM4B-35 高表达与子宫内膜癌的进展和预后有关。
